» Articles » PMID: 39274302

Real-World Practices of Pentosan Polysulfate Maculopathy Screening in Various Clinical Settings and Practice-Associated Factors

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Sep 14
PMID 39274302
Authors
Affiliations
Soon will be listed here.
Abstract

: This study investigated the practice patterns of pentosan polysulfate (PPS) maculopathy screening in various clinical settings and demographic and clinical characteristics associated with these screening practices using a health claims database. : In this nationwide population-based study, data from the Health Insurance Review and Assessment database in South Korea were analyzed to identify patients who underwent PPS. The participants were categorized based on whether they had undergone a baseline examination (the first ophthalmic examination since PPS prescription) within one year of PPS use, subsequent monitoring within one year of the baseline examination, or recent monitoring within a 1-year period before the study end date. Demographic and clinical factors were compared between the groups, and factors associated with screening practices were identified using logistic regression analyses. : Significant differences in screening practices were observed based on sex, age, residence, the medical specialty of the prescribing physician, indications for PPS use, and hospital type of prescription. Older patients who received PPS prescriptions from urologists were more likely to undergo baseline and monitoring examinations. Logistic regression analyses revealed that older age, female sex, and a longer duration of PPS use were significantly associated with baseline screening. Subsequent and recent monitoring was significantly associated with age, duration of PPS use, and treatment at primary hospitals. : This study underscores the variability in screening practices for PPS users based on demographic and clinical factors, emphasizing the need for standardized guidelines. Enhanced awareness and timely referral for maculopathy screening, particularly among non-urological specialties, are essential.

References
1.
Paredes Mogica J, De E . Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020. Urology. 2020; 147:109-118. DOI: 10.1016/j.urology.2020.08.072. View

2.
Ludwig C, Vail D, Callaway N, Pasricha M, Moshfeghi D . Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States. Ophthalmology. 2020; 127(4):535-543. DOI: 10.1016/j.ophtha.2019.10.036. View

3.
Rosenbaum J, Costenbader K, Desmarais J, Ginzler E, Fett N, Goodman S . American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis Rheumatol. 2021; 73(6):908-911. DOI: 10.1002/art.41683. View

4.
Mukhopadhyay C, Boyce T, Gehrs K, Folk J, Mullins R, Luo Y . Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice. Asia Pac J Ophthalmol (Phila). 2022; 11(2):100-110. PMC: 9096915. DOI: 10.1097/APO.0000000000000504. View

5.
Hanif A, Armenti S, Taylor S, Shah R, Igelman A, Jayasundera K . Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study. JAMA Ophthalmol. 2019; 137(11):1275-1282. PMC: 6735406. DOI: 10.1001/jamaophthalmol.2019.3392. View